Navigation Links
TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
Date:12/1/2008

SAN DIEGO, Dec. 1 /PRNewswire/ -- TargeGen has announced that an oral presentation of preliminary results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of Hematology (ASH) Meeting.

    Details of the presentation are as follows:

    Title:              A Phase I Study of TG101348, an Orally Bioavailable
                        JAK2-Selective Inhibitor, in Patients with
                        Myelofibrosis
    Presenter:          Dr. Animesh Pardanani, Mayo Clinic
    Session Name:       Myeloproliferative Disorders-Experimental Therapeutics
    Session Date:       Sunday, December 7, 2008
    Presentation Time:  4:30 PM
    Room:               Moscone Center SOUTH, Rooms 304-306-308
    Directions:         Howard Street entrance, turn left, up 2 flights of
                        stairs to Esplanade level

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases. TargeGen initiated operations in 2002 and has raised capital from top tier venture capital sources. Current investors include VantagePoint Venture Partners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BB BIOTECH VENTURES, Innovis Investments, H&Q Capital Management, Pappas Ventures, CTI Life Sciences and other investors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)


'/>"/>
SOURCE TargeGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
2. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
3. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
4. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
5. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
6. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
7. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
10. Cytopia Scientific Presentations on JAK2 Inhibitor Program
11. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... LONDON , July 31, 2014 ... for the medical industries, announced today the incorporation of genae UK ... United Kingdom has one of the largest medical device ... in 2012 and it is projected to increase by a CAGR ... billion in 2012, equal to 9.5% of GDP. Despite recessionary pressures, ...
(Date:7/31/2014)... July 31, 2014 Astellas has appointed ... corporate and employee communications in the Americas region. ... , senior vice president, chief communications officer. In ... and leading corporate brand initiatives and reputation management ... and South America . She ...
(Date:7/31/2014)... 2014 The Galien Foundation today announced the ... USA Awards. The Prix Galien Award ... the technical, scientific and clinical research skills necessary to ... brings the highest number of nominees since the inception ... Nominees include biomedical products across three categories – biotechnology, ...
Breaking Medicine Technology:genae Opens Offices in London 2Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
... , DUBLIN, Ohio , July 15 Cardinal ... LLC, expanding the company,s presence in specialty pharmaceutical services. , ... Healthcare Solutions Holding ... Pathways and P4 Healthcare. These businesses serve key participants across the ...
... , SAN MATEO, Calif. , July 15 Merz ... to doctors, offices throughout the U.S.  Previously only available in Europe ... (FDA). , , , ... study published in the June issue of Phlebology , leading experts ...
Cached Medicine Technology:Cardinal Health Completes Acquisition of Healthcare Solutions Holding 2Cardinal Health Completes Acquisition of Healthcare Solutions Holding 3Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 2Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 3Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 4
(Date:7/31/2014)... (PRWEB) July 31, 2014 The ... the hiring of new dentist Dr. Jonathan Oudin, DDS, ... had previously practiced in Barrow, Alaska, for three years. ... for Dentistry hired Dr. Oudin to help take on ... for Dentistry to continue growing and serving the greater ...
(Date:7/31/2014)... reporting cognitive difficulties after a head injury are usually ... really a concussion? A new study published by University ... same symptoms are common to concussions and to injuries ... cervical/vestibular injuries. , The research was based on responses ... were professional athletes who were being treated at ...
(Date:7/31/2014)... Millions of people avoid going to ... experiences as a child and some simply fear the ... a highly experienced NJ cosmetic dentist, Dr. Richard Champagne ... dental procedure. To help these patients receive the ... Smiles offer several sedation dentistry techniques. , Sedation dentistry ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Transvaginal mesh ... continue to move forward in the federal multidistrict litigation ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... consider certain defense motions now pending before the Court. ... Magistrate Judge on Tuesday, August 5th at 2:30 p.m. ...
(Date:7/31/2014)... 2014 Model moms are believers. PBS has ... positions in the field have grown exponentially in the last ... thriving industry, there are associated myths that need to be ... Frontier Nursing University . Celebrating 75 years in 2014, ... in the nation. “Frontier is changing the face of ...
Breaking Medicine News(10 mins):Health News:Dr. Jonathan Oudin to Join Alaska Center for Dentistry at Wasilla Location 2Health News:Is it really a concussion? Symptoms overlap with neck injuries so diagnosis is tough call 2Health News:Is it really a concussion? Symptoms overlap with neck injuries so diagnosis is tough call 3Health News:Champagne Smiles is Thrilled to Now Offer Sedation Dentistry to their Patients 2Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 2Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 2Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 4Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 5
... need for more talking therapies for people with depression//. ... two talking therapy pilot centers in Doncaster and Newham, aimed ... to work. If it succeeded other centers could also be ... says evidence from its helpline callers show 83% take medication ...
... by scientists at UCSF, Celera Genomics and The Cleveland Clinic ... heart attack, or myocardial infarction (MI). ,One of ... for early stages of clotting. When clotting occurs in a ... gene mutations that increase heart attack risk can help identify ...
... from cigarette smoke of parents can affect their infants. The ... are associated with tobacco smoke in the urine of nearly ... ,"The take home message is, 'Don't smoke around your kids,'" ... Cancer Prevention at The Cancer Center at the University of ...
... is time for the medical students in Scotland to voice ... held demonstrations //outside the Scottish Parliament to show their disapproval. ... were very much close to the top-up fees. But ministers ... fees. , But last year the Scottish ministers ...
... has cut down payments for health care providers. Angered ... //in to this matter. The insurers reduce payment to ... are forced out of practice and have to turn ... this MedChi said in a letter to Attorney General ...
... shrouded in ambiguity, though studies have hinted at the ... a novel report has suggested that growth hormone, as ... of calorie restriction and does contribute to extending life. ... University in Springfield and his team studied the effects ...
Cached Medicine News:Health News:Gene Variants Linked to Early Heart Attack Discovered 2Health News:Gene Variants Linked to Early Heart Attack Discovered 3Health News:Gene Variants Linked to Early Heart Attack Discovered 4Health News:Cancer Causing Chemicals Found In Urine Of Babies Whose Parents Smoke 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
Medicine Products: